X0306
4
2021-01-04
0
0001609550
Inspire Medical Systems, Inc.
INSP
0001737127
Ban Randy
C/O INSPIRE MEDICAL SYSTEMS, INC.
5500 WAYZATA BLVD., SUITE 1600
GOLDEN VALLEY
MN
55416
0
1
0
0
Chief Commercial Officer
Common Stock
2021-01-04
4
M
0
15000
2.07
A
15229
D
Common Stock
2021-01-04
4
M
0
15187
1.14
A
30416
D
Common Stock
2021-01-04
4
S
0
7347
180.55
D
23069
D
Common Stock
2021-01-04
4
S
0
8760
181.55
D
14309
D
Common Stock
2021-01-04
4
S
0
8326
182.36
D
5983
D
Common Stock
2021-01-04
4
S
0
1374
183.31
D
4609
D
Common Stock
2021-01-04
4
S
0
1522
184.57
D
3087
D
Common Stock
2021-01-04
4
S
0
2508
185.51
D
579
D
Common Stock
2021-01-04
4
S
0
300
186.11
D
279
D
Common Stock
2021-01-04
4
S
0
50
187.26
D
229
D
Common Stock
167
I
By son
Common Stock
166
I
By daughter
Stock Option (Right to Buy)
2.07
2021-01-04
4
M
0
15000
0
D
2024-03-31
Common Stock
15000
12067
D
Stock Option (Right to Buy)
1.14
2021-01-04
4
M
0
15187
0
D
2023-09-12
Common Stock
15187
0
D
Includes 40 additional shares acquired under the Inspire Medical Systems, Inc. (the "Company") 2018 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on September 11, 2020.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.00 to $180.98. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.01 to $182.00. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $182.01 to $182.92. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.01 to $183.94. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $184.01 to $184.95. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $185.04 to $186.01. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $186.04 to $186.17. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The option is fully vested and exercisable.
/s/ Richard Buchholz, as Attorney-in-Fact for Randy Ban
2021-01-06